RANDOLPH HENRY BRETTON, JR
Pilots at Pro Tour Dr, Belleville, IL
License number
Illinois A2455884
Issued Date
Jan 2017
Expiration Date
Jan 2019
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
2440 Pro Tour Dr, Belleville, IL 62220
Professional information
Randolph Henry Bretton Jr., Belleville IL - Lawyer
Address:
2440 Pro Tour Dr, Belleville 62220
(314) 704-2060
(314) 704-2060
Licenses:
Missouri - Good Standing, Active 2005
Specialties:
Intellectual Property - 100%
Intraocular Lens Implant For The Prevention Of Secondary Cataracts
US Patent:
6454802, Sep 24, 2002
Filed:
Aug 21, 2000
Appl. No.:
09/642966
Inventors:
Randolph H. Bretton - Belleville IL
David P. Vanderbilt - St. Louis MO
George F. Green - St. Louis MO
David P. Vanderbilt - St. Louis MO
George F. Green - St. Louis MO
Assignee:
Bausch Lomb Incorporated - Rochester NY
International Classification:
A61F 216
US Classification:
623 661, 623 662
Abstract:
A surface treated intraocular lens implant for use in the replacement of a cataractous natural lens to prevent posteriror capsular opacification. The surface treated intraocular lens includes one or more proteins, polypeptides, polyamino acids or polyamines bound to the surface of the intraocular lens implant covalently, non-covalently or a combination thereof. The one or more proteins, polypeptides, polyamino acids or polyamines present on the surface of the intraocular lens implant serves to reduce or eliminate residual lens epithelial cell migration within the lens capsule. By preventing residual lens epithelial cell migration, posterior capsular opacification of the intraocular lens implant is thus reduced or eliminated.
Intraocular Lens Implants For The Prevention Of Secondary Cataracts
US Patent:
6106554, Aug 22, 2000
Filed:
Feb 25, 1999
Appl. No.:
9/257678
Inventors:
Randolph H. Bretton - Belleville IL
Assignee:
Bausch & Lomb Surgical, Inc. - Claremont CA
International Classification:
A61F 216
US Classification:
623 662
Abstract:
A surface treated intraocular lens implant for use in the replacement of a cataracts natural lens to prevent posterior cellular opacification. The surface treated intraocular lens includes one or more carbohydrates covalently bound to the surface of the intraocular lens implant and a carbohydrate binding agent conjugated to a cytotoxic agent for binding said carbohydrates. The cytotoxic agent present on the intraocular lens implant serves to destroy residual lens epithelial cells within the lens capsule thereby preventing posterior cellular opacification of the intraocular lens implant.